Episode Details

Back to Episodes
Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline

Apogee-AbbVie; Regenxbio and FDA News; SpaceX Decline

Published 3 months, 3 weeks ago
Description

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Apogee (APGE) shares are soaring on news AbbVie is closing in on a nearly $11 billion deal to buy inflammatory disease drug developer Apogee Therapeutics. That's also according to a Financial Times report.
- Regenxbio (RGNX) shares are moving on news Regenxbio aligned with the FDA on next steps for a potential accelerated approval of Navsunli, a gene therapy for Mucopolysaccharidosis II, with the FDA confirming the company doesn’t need to conduct additional studies of the drug.
- SpaceX (SPCX) is lower this morning, continuing its slide after its record IPO.

See omnystudio.com/listener for privacy information.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us